Arlington Trust’s Myriad Genetics MYGN Stock Holding History

Arlington Trust’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-145	Closed	-$2.77K	–	744
2023 Q4	$2.77K	Buy	+145	New	+$2.51K	﹤0.01%	567

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Arlington Trust's MYGN Position: Q1 2024 in Review

Arlington Trust sold out of Myriad Genetics (MYGN) in Q1 2024, closing a stake of 145 shares — an estimated $2.77K sold.

Arlington Trust first reported a position in MYGN in Q4 2023 and held it in 1 quarter. The position peaked at $2.77K in Q4 2023. 186 funds tracked by Wall St. Rank hold MYGN as of Q1 2024.

Arlington Trust reported no remaining Myriad Genetics position as of Q1 2024 after selling out during the quarter.
Arlington Trust sold 145 Myriad Genetics shares in Q1 2024, an estimated $2.77K.
Arlington Trust first reported a position in Myriad Genetics in Q4 2023 and held it in 1 quarter.
Arlington Trust's Myriad Genetics position peaked at $2.77K in Q4 2023.
186 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2024.

Based on Arlington Trust's 13F filing for Q1 2024, filed 16 Apr 2024.